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The NIH Lasker Clinical Research 
Scholars Program 
A Unique Bridge for Early Stage Clinical 
Investigators 
The National Institutes of Health, in partnership with the 
Lasker Foundation, is pleased to announce the 2015 Lasker 
Clinical Research Scholars Program. This is an 
opportunity for 10 to 12 years of funding for clinical 
researchers. 
This unique program provides Scholars with 5 to 7 years of 
support as an independent principal investigator in the NIH 
Intramural Research Program, followed by three years of 
continued financial support, either at the NIH or at an 
outside medical center/research institution. 
 
Qualifications/eligibility: 
Candidates must have a clinical doctoral degree (MD, 
MD/PhD, DO, DDS, DMD, RN/PhD or equivalent) and a 
professional license to practice in the United States. The 
program is intended for investigators at the early stages of 
their independent careers, and at the time of application, 
candidates must be no more than 10 years from completion 
of their core residency training. Candidates generally will 
have completed or will be completing a post-residency 
clinical fellowship and will have demonstrated significant 
patient-oriented research experience to qualify for a tenure-
track level appointment. 
 
To apply: Learn more at 
http://www.nih.gov/science/laskerscholar/ 
 
Application deadline is August 27, 2015 
 
Questions can be directed to Dr. Charles Dearolf, Assistant 
Director for Intramural Research, at LaskerScholar@nih.gov 
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M2D2 Opens Fully Equipped Shared Lab Space 
The Massachusetts Medical Device and Development Center (M2D2) has opened an additional center 
with fully-equipped shared lab and collaborative space at 110 Canal Street in Lowell, MA 
Rates have been set and tours are available. If you are interested in the new facility, please contact Mary 
Ann Picard either by email at M2D2@uml.edu or by telephone at 978-934-3465. 
M2D2 will provide: 
• Lab space 
• Lab equipment with maintenance and technical support 
• Lab training and EHS compliance 
• Educational programming for start-up companies 
• Access to UMass Medical School resources 
• Access to UMass Lowell business, engineering and prototyping resources 
• Secure access 
• Waste removal 
• Parking and easy access to MBTA Commuter Rail 
• Conference rooms and meeting space 
• Co-worker and kitchen café area 
• Internet 
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 How to Share Your Science 
 
Suspend Your Judgment for a Moment 
 
Sally A. Gore, MS, MSLIS, Research Evaluation Analyst, UMCCTS 
Altmetrics, alternative metrics, article level metrics … in the arena of scholarly 
and scientific publishing, you may have noticed any and/or all of these terms cropping 
up. You may have seen widgets on the sites of your published on-line articles, 
prompting visitors to share the content via different social media channels. You may 
have noticed the ability to comment on abstracts and articles in popular databases 
like PubMed (see “PubMed Commons”). You may have received emails telling you that 
a certain number of people have downloaded your article over a particular period of 
time. You may be suspicious of these new tools and believe they hold little value to 
the biomedical research community. You may think Twitter is only a place for people 
to post pictures of kittens (I once had a researcher tell me this), but to deny the 
importance and usefulness of alternative means of both disseminating and measuring 
the impact of your research is to do a disservice to yourself and the stakeholders 
behind your funding. 
Traditional publishing metrics such as the h-index and impact factor are still important 
and still widely accepted as the norm and/or gold standard for things like promotion 
and tenure, but alternative metrics have developed over the past few years to provide 
a bigger, more robust, and complementary picture of how science reaches beyond the 
academy and professional circles of peers. 
A couple of examples: 
In 2010, the UMCCTS provided funding for a pilot project, “A Community-Based Social Networking 
Intervention to Increase Walking in Dog Owners” (Schneider, Lemon, Oleski, Murphy, and Ferrara). 
A randomized control trial followed and in 2015, Schneider et al published a manuscript in the journal, 
“Medicine and Science in Sports and Exercise.” MSSE has a healthy journal impact factor, consistently 
ranking near the top in its discipline (Sport Sciences). It’s widely respected and getting this manuscript 
published in it bodes well for the authors’ careers. But beyond that, what does it say? Does publication in 
this journal reach the community; a group that might establish a similar program to increase participants’ 
health? Does it reach clinicians who might suggest to their dog owner patients the health benefits of such 
a program? Does it reach policy makers who could provide funding for more trails and 
walking paths? Perhaps, but more than likely, these stakeholders will be reached via 
different channels of communication besides journal articles and one way to track 
these is via alternative metrics. 
Using a tool like Altmetric, an author, evaluator, or reader can quickly and easily see 
another view of the impact of this particular article. Looking up the Altmetric score for 
this article, we can see that it was mentioned on the social media outlets Twitter, 
Facebook, and Google+. Sixteen people on Twitter shared the link to the article with 
their followers. “So what?” you may say, “That’s not many people.” But if you look a 
bit deeper you’ll find that these 16 users mentioned and shared the article 22 times to 
their followers. How many followers? 15,455. Even if the smallest percentage of those 
followers looked at the article, it’s reached several hundred people that it likely 
wouldn’t have reached through older, more traditional means. Further, the people 
sharing the message were researchers, students, science writers, and members of the 
general public, all representing different stakeholders. 
Skeptics will say that this was an article about social media and dog walking, so of course it gets shared 
through social media. Puppies and kittens, remember? They claim that “real” science isn’t followed the 
same. Think again. UMCCTS Life Sciences Moment Fund Awardee, Douglas Golenbock, MD, recently 
published the article, “Neuroinflammation in Alzheimer’s Disease”, in the journal, “Lancet Neurology.” 
dis·sem·i·nate  
/di-ˈse-mə-ˌnāt/ 
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It, too, has made an impact via alternative channels as shown by its corresponding Altmetric score. The 
article has been written about on a blog, shared via Twitter 15 times (5,000+ followers), discussed on 
Weibo, a major social network in China, appeared on 2 Facebook pages, and cited on the social 
bookmarking site, CiteULike. In short, it’s reaching an audience well beyond subscribers to the Lancet.  
This is a trend that really can’t simply be ignored anymore today. For those practicing clinical and 
translational medicine, building trans-disciplinary collaborations and partnerships is a barrier that must be 
overcome if success is to be achieved. Communicating one’s research widely is one way to find partners 
who may have, in a time before our networked world, remained unknown. It’s a way to build 
collaborations with community leaders and policy makers, bringing the valuable findings of medical 
research to the public much faster. It’s a way to reach traditional media outlets and thus, an even wider 
audience. And finally, it’s a means to create a more scientifically literate society, something that benefits 
everyone in the end. 
 
Interesting in learning how to track your work with alternative metrics? Contact Sally 
(sally.gore@umassmed.edu) for help. 
 
 
Progress Report Update: UMCCTS Clinical Research Scholar 
(K12) Award 
Sally A. Gore, MS, MSLIS, Research Evaluation 
Analyst, UMCCTS
 
The Clinical Research Scholar Awards provide 
training, mentorship, and funding for 
investigators to develop and carry out innovative, 
hypothesis-driven clinical and translational 
research. The UMCCTS currently funds six K12 
Scholars:  
• Melissa Anderson, PhD 
• Nancy Byatt, DO, MBA 
• Sarah Cutrona, MD, MPH 
• David McManus, MD 
• Heena Santry, MD, MS 
• Molly Waring, PhD 
The latest progress reports submitted by these 
Scholars show a wealth of research, scholarship, 
and growth as clinical investigators.
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Common Questions on Clinical Trial Agreements 
UMCCTS Office of Clinical Research (OCR) Staff provide helpful tips and 
information to investigators, study teams and departments 
Tips for: A Smooth Budget Negotiation Process 
Elena Del Prete, MS, MBA, Contract Administrator II – Budget Specialist 
• Evaluate the actual cost of doing the study and what it will take to cover all costs--Don’t assume 
that the budget is not negotiable; 
• Include all costs, including costs for institutional resources and cores (Investigational Drug Service, 
Clinical Research Center) and patient care costs (testing, facility use); 
• Carefully review protocol and procedure requirements, and clarifying with sponsor if applicable, to 
ensure the budget captures all associated costs; 
• Perform all applicable billing compliance steps, such as a Qualifying Clinical Trial assessment and 
Coverage Analysis; 
• Be sure to ask for startup fees!—to help OCR negotiate the budget, prepare and provide a 
justification outline of investigator and study team start-up fees; 
• Ask for additional invoiceable items for regulatory work for AEs, monitoring; 
• Accurate budgeting is critical for feasibility, in negotiations with sponsors, with patient billing and 
project financial management; and 
• Provide OCR negotiator with areas of flexibility on the budget template and a clearly defined 
bottom line. 
 
Contact the Office of Clinical Research for assistance at clinicalresearch@umassmed.edu 
or check out the website at http://www.umassmed.edu/ccts/human-research/Clinical-Research-
Agreements-and-Budgets/ 
 
  
5
: UMCCTS Newsletter, June 2015
Published by eScholarship@UMMS, 2015
UMCCTS Newsletter June 2015  6 
 
The Bioinformatics Core invites you to: An Informal Discussion 
Population Structure and Gene Regulatory Linkage from Single 
Cell Droplet RNA Sequencing 
 
Allon Klein, PhD 
Assistant Professor of Systems Biology, Harvard University 
 
Friday, June 12, 2015 
11:00 AM 
6th Floor Conference Room 2072 
Albert Sherman Center 
University of Massachusetts Medical School 
 
 
 
University of Massachusetts Medical School 
Program in Molecular Medicine Special Seminar 
 
Guadalupe Sabio, D.V.M., Ph.D. 
Department of Vascular Biology & Inflammation 
CNIC, Madrid, Spain 
http://www.sabiolab.com/ 
 
p38γ and δ Promote Heart Hypertrophy by Targeting the mTOR-
inhibitory Protein DEPTOR for Degradation 
 
Monday, June 22, 2015 
11:00 am 
Biotech II, 373 Plantation Street 
3rd Floor Seminar Room 
University of Massachusetts Medical School 
Host: Roger J. Davis, PhD., Professor, Program in Molecular Medicine 
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A Survey of Clinical Opinion on the Utility of 
Point-of-Care Testing (POCT) Devices 
As part of an inter-institutional MOU, the UMass Center for Clinical and Translational Science (UMCCTS) is 
facilitating a research project with the University of Ulster, Nanotechnology & Integrated Bioengineering 
Centre, School of Engineering, Northern Ireland regarding the clinical utility of point-of-care testing 
(POCT) devices. A PhD student, Alistair Quinn, will be at the University of Massachusetts Medical School 
June 7-19, 2015 conducting 30 minute physician interviews. 
What is the purpose of the study? 
There are indications from published literature that despite rapid advances in the development of new 
diagnostic markers that underpin the clinical utility of POCT, the uptake and utilization of these 
technologies is less than might be expected. The nature and relative importance of the issues that have 
been identified as possible impediments to the more widespread adoption of POCT are not fully 
understood. To better explain these underlying issues, it is deemed important to gain relevant information 
as to the utility of POCT devices within the clinical environment. As POCT is used internationally, it is 
important to compare experiences in a range of countries operating within different healthcare provision 
regimens. 
A complete description of the study is available on the UMCCTS website at, 
http://www.umassmed.edu/ccts/news/2015/June/point-of-care-testing 
If you are interested in participating in this study, please contact Nate Hafer, PhD, 
nathaniel.hafer@umassmed.edu 
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The National Center for Advancing Translational Sciences 
Collaborative Innovation Award 
The National Center for Advancing Translational Sciences (NCATS), National Institutes of Health has 
announced a Collaborative Innovation Award, Clinical and Translational Science Award (CTSA) 
Program U01 and pre-application X02. 
These FOAs aims to support applications for innovative collaborative investigations (involving three or 
more CTSA sites) into improvements of the methods of translational research, at any step in the 
translational spectrum (T1-T4). It is anticipated that the combined effort of three or more CTSA hubs in 
flexible networks will substantially enhance the effectiveness of the CTSA consortium to address high 
priority translational research questions. These FOAs therefore aim to support innovative and collaborative 
experimental translational research projects carried out in the CTSA consortium that have the following 
characteristics: 
• Such projects should develop a new technology, method, or approach that addresses a general 
roadblock in science and/or operations that limits the efficiency and effectiveness of translation. 
• Such projects should demonstrate in one or more use cases whether the tool, method, or approach 
is effective in accelerating translation, utilizing clear and meaningful metrics and outcomes, when 
implemented across multiple CTSA hubs. 
• Such projects should advance collaboration, building on existing strengths and resources of 
individual CTSA hubs. 
• What constitutes success of the proposed project can be defined and measured. 
 
Please see complete details in the 2 links below:  There is a pre-application step (X02) followed by 
an invited full application (U01). 
X02 URL: http://grants.nih.gov/grants/guide/pa-files/PAR-15-173.html 
U01 URL: http://grants.nih.gov/grants/guide/pa-files/PAR-15-172.html 
If you are interested in submitting a pre-application, please contact Nate Hafer at least 2 weeks 
before the grant deadline at nathaniel.hafer@umassmed.edu or 508-856-2511 
 
 
 
The National Center for Advancing Translational Sciences and 
National Library of Medicine 
Clinical and Translational Science Award (CTSA) Network 
Recruitment Innovation Centers (RICs) (U24) 
The National Center for Advancing Translational Sciences (NCATS) and National Library of Medicine, 
National Institutes of Health has just announced a new Clinical and Translational Science Award 
(CTSA) Network Recruitment Innovation Centers (RICs) (U24). 
Translating laboratory and clinical discoveries into interventions that improve human health is a complex 
process that typically takes years of effort. Multi-site clinical trials are a critical step in the translation 
pathway that allows preventive, diagnostic, or therapeutic interventions to benefit individual and public 
health. These trials may require substantial sample sizes to credibly test hypotheses. However, such trials 
often experience delays or even fail entirely due to challenges in recruiting participants. Such challenges 
are a multi-faceted problem with scientific, psychological, sociological, economic, political, and ethical 
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dimensions. Addressing these challenges therefore requires a multi-faceted and “out of the box” approach, 
rather than small changes only to the status quo. Participant recruitment may benefit from innovation in 
the following areas: 
• Access to data on the availability of potential participants rather than reliance on clinician 
estimates. 
• Data that provide sufficient detail to take into account the specific entry criteria of a given protocol. 
• Recruitment strategies that employ innovative approaches from other fields such as 
communications.  
• Sharing of recruitment strategies, materials, and associated outcomes among participating 
research sites or between projects for ongoing innovation and improvement so that best practices 
can be developed and disseminated. 
• Engagement of relevant stakeholders (e.g. potential participants and referring clinicians) early in 
the recruitment process. 
• Reducing burden on participants, and making referrals easy for busy clinicians who may have many 
priorities competing for their time. 
• Reframing proposed solutions to recruitment challenges as testable scientific hypotheses to allow 
for data-driven process selection. 
This FOA is intended to develop and implement innovative informatics-driven approaches as well as the 
ethics and policy frameworks that will accelerate the design, conduct, and completion of multi-site clinical 
trials by establishing Clinical and Translational Science Award (CTSA) Recruitment Innovation Centers 
(RICs). 
Please see complete details in the link below: 
http://grants.nih.gov/grants/guide/rfa-files/RFA-TR-15-004.html 
 
If you are interested in submitting an application, please contact Nate Hafer as soon as possible at 
nathaniel.hafer@umassmed.edu or 508-856-2511 
 
 
 
The National Center for Advancing Translational Sciences and 
National Institute on Aging 
CTSA Network – Trial Innovation Centers (TICs) (U24) 
The National Center for Advancing Translational Sciences (NCATS) and National Institute on Aging, 
National Institutes of Health has just announced a new Clinical and Translational Science Award 
(CTSA) Network – Trial Innovation Centers (TICs) (U24). 
The purpose of this funding opportunity announcement is to invite applications to establish Trial 
Innovation Centers (TICs) for the Clinical and Translational Science Award (CTSA) program. The TICs will 
be lead centers of an innovative expert network that will accelerate the implementation of multi-site 
studies by the CTSA Network. National Institutes of Health (NIH) supported studies are the focus of this 
initiative; however, the capacity created might also be of interest and useful for trials conducted by other 
federal agencies, as well as by the private and non-profit sectors. 
The TICs will transform the CTSA network’s ability to implement multi-site studies by adding innovative 
network capacity to the existing strength at the CTSA Hubs. The TICs will not be specific to one disease, 
but have the capacity to identify and coordinate a cadre of specialist investigators from across the CTSA 
network to implement studies efficiently in response to a broad range of disease specific opportunities. 
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Select TICs, however, will have particular expertise to conduct multi-site studies with special populations, 
such as pediatric or geriatric subjects. 
 
Please see complete details in the link below: 
http://grants.nih.gov/grants/guide/rfa-files/RFA-TR-15-002.html 
 
If you are interested in submitting an application, please contact Nate Hafer as soon as possible at 
nathaniel.hafer@umassmed.edu or 508-856-2511 
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Pfizer’s Centers for Therapeutic Innovation (CTI) 
Request for Translational Proposals: Biotherapeutic and Small Molecule Targets 
CTI is an innovative Pfizer program that partners with leading academic medical centers and patient 
foundations nationwide to speed the translation of novel targets into potential therapeutics. CTI seeks to 
identify and partner novel targets with the goal of identifying new compounds and accelerate drug 
development from validated target to proof-of-mechanism in humans. A partnership with CTI may include 
collaborative use of Pfizer’s proprietary antibody drug delivery technologies and/or compound library, 
broad publishing rights and financial awards in the form of milestone and royalty payments for successful 
programs. 
Deadline date: Friday, June 12, 2015 
 
Large & Small Molecule Modalities in Scope 
› Large Molecules: Antibodies, Proteins, Peptides 
› Small Molecules: Kinases, Serine hydrolases, 
Solute transporters, Epigenetic targets 
 
Therapeutic Areas of Interest: 
• Inflammation 
• Autoimmunity 
• Tissue remodeling 
• Oncology 
• Cancer Immunology 
• Rare or genetic diseases 
• Cardiovascular and metabolic diseases 
• Neuroscience 
 
More information on Pfizer’s therapeutic 
areas of interest can be found at: 
www.pfizer.com/research/therapeutic_areas 
 
Note that CTI partners with several 
Foundations with common research 
interests: 
• Alliance for Lupus Research (ALR) 
• Juvenile Diabetes Research Foundation 
(JDRF) 
• Crohn’s & Colitis Foundation of America 
(CCFA) 
• Foundation of Sarcoidosis Research (FSR) 
• Alzheimer's Drug Discovery Foundation 
(ADDF) 
 
What We Look For: 
› Strong Project Rationale: Demonstrated 
association between target biology and disease 
mechanism 
› Ability to Address Unmet Medical Needs 
› Validated Therapeutic Drug Target: Strong 
link from targeted pathway to disease, and a 
tractable target relative to proposed drug 
modalities 
› Feasibility: Plan to candidate development and 
translation into the clinic 
› Clinical Differentiation: Opportunity for 
underpinning therapeutic strategy via patient 
stratification, molecular signatures, genetic 
associations, biomarkers 
 
 
Proposal Submission Process: 
› The Pre-Proposal is a brief NON-CONFIDENTIAL 
2-3 page overview of the mechanism and 
proposed research plan to demonstrate proof of 
mechanism (template available in the UMCCTS 
website link below) 
› Submit the Pre-Proposal to one of the 
contacts noted below by June 12, 2015 who 
will then submit for review by the Joint Steering 
Committee via the CTI portal 
 
All researchers, clinicians and post-docs whose work meets these criteria are invited to apply. For more 
information, please contact: Venkat Reddy, Venkateshwar.Reddy@pfizer.com or Nate Hafer, 
Nathaniel.Hafer@umassmed.edu 
Please go to the UMCCTS website for complete details: http://www.umassmed.edu/ccts/funding/ 
  
11
: UMCCTS Newsletter, June 2015
Published by eScholarship@UMMS, 2015
UMCCTS Newsletter June 2015  12 
 
Overview 
In 1991, the Smith Family Foundation created a grants program to support promising junior faculty who 
were beginning to establish their own independent laboratories and research programs. Now in its 24th 
year, this Program has funded 143 scientists for a total of $26.9 million. 
Application for the Smith Family Awards Program for Excellence in Biomedical Research may focus on all 
fields of basic biomedical science. Investigators in the physical sciences (physics, chemistry and 
engineering) with biomedical research projects are also encouraged to apply. 
Online Application Deadline: Thursday, September 3, 2015 at 12:00 noon EST 
Funding Period: December 1, 2015 – November 30, 2018 
Award Amount: Up to $300,000 three-year awards, inclusive of 5% institutional overhead. 
For complete information: www.tmfgrants.org/Smith 
 
 
The Smith Family Awards Program for Excellence in Biomedical 
Research is managed by The Medical Foundation division. 
 
Funding for Alzheimer’s Disease 
Drug Discovery Research 
Edward N. & Della L. Thome Memorial 
Foundation, Bank of America, N.A., 
Trustee, Awards Program in Alzheimer’s 
Disease Drug Discovery Research 
The Edward N. & Della L. Thome Memorial Foundation was created in 2002 to advance the health of older 
adults through the support of direct service projects and medical research on diseases and disorders 
affecting older adults. 
The goal of the 2015 Awards Program in Alzheimer’s Disease (AD) Drug Discovery Research is to support 
innovative drug discovery research that will lead to improved therapies for individuals suffering from 
Alzheimer’s disease. 
Researchers dedicated to the validation and testing of target compounds and therapeutic 
agents, including biologics and small molecules, are encouraged to apply. Consideration will be 
given to research based on the amyloid hypothesis as well as alternative pathogenic mechanisms such as 
APOE, inflammatory and tau-related pathways. 
Basic research or new target discovery, genetic studies, biomarker research, neuro-imaging and clinical 
studies are currently outside the scope of this Program. 
Initial Proposal Deadline: Friday, June 26, 2015, 12:00 noon EST 
Award Amount and Funding Period: Two-year projects of $500,000 and up to 6 awards will be funded 
Funding begins on December 31, 2015 
Guidelines and Materials: www.tmfgrants.org/ThomeAD 
 
 
The Edward N. & Della L. Thome Memorial Foundation Awards 
Program is administered by The Medical Foundation division. 
Questions: 617-279-2240 X710, or EJohnstone@hria.org 
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National Institutes of Health 
Department of Health and Human Services 
NIH Transformative Research Awards (R01) 
RFA-RM-15-005 
The NIH Transformative Research Awards complement NIH’s traditional, investigator-initiated grant 
programs by supporting individual scientists or groups of scientists proposing groundbreaking, 
exceptionally innovative, original and/or unconventional research with the potential to create new 
scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative 
technologies. Little or no preliminary data are expected. Projects must clearly demonstrate the potential to 
produce a major impact in a broad area of biomedical or behavioral research. 
Complete details: http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-15-005.html 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UMass Center for Clinical and Translational Science 
362 Plantation Street, Ambulatory Care Center, 7th Floor 
Worcester, MA  01605-0002 
 
Website:  http://www.umassmed.edu/CCTS 
Email:  ccts@umassmed.edu 
Contact us:  http://www.umassmed.edu/ccts/contact-us/ 
Sign-up for Membership:  http://www.umassmed.edu/ccts/ccts-sign-up-for-membership/ 
 
Please remember to cite the CTSA Grant # UL1TR000161 in all supported journal publications. 
http://www.umassmed.edu/ccts/nih-citation-requirements/ 
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